73 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
on the Innovation Advisory Council for Foundation Fighting Blindness and the Editorial Board of Journal of Ocular Pharmacology and Therapeutics.
Nirav Jhaveri
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
it may pursue could be significantly diminished.
Ocuphire may rely upon trade secrets, know-how, and continuing technological innovation to develop
8-K
EX-99.2
c1vv47ev7ksnsr jj8
19 May 22
Regulation FD Disclosure
7:43am
8-K
EX-99.1
kdm fgnae
24 Mar 22
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update
8:17am
8-K
EX-99.1
lpeisz5q3tmjj3g
5 Jan 22
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
7:05am
8-K
EX-99.1
9boup486koo
15 Nov 21
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12:00am
8-K
EX-99.1
i3u 88qx7fg
12 Aug 21
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
7:31am
424B5
ulxiyc6mt7 4r
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
frpa 9f9x4s
7 May 21
Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update
4:01pm
424B5
634sxxtc
11 Mar 21
Prospectus supplement for primary offering
9:19am
8-K
EX-99.1
s6dhtl1
11 Mar 21
Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update
9:12am